Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nymox Pharmaceutical has released positive long term efficacy results from phase I-II testing of NX-1207, the company's investigational new drug for benign prostatic hyperplasia.
Subscribe to our email newsletter
The newly-released data indicates that at 29 to 34 months after initial treatment, there was highly significant symptomatic improvement. There were no serious safety issues reported in individuals treated with NX-1207.
Patients in the trial who were available for follow-up were administered AUA symptom score evaluations after periods of 29 to 34 months post treatment.
The mean AUA score in patients treated with NX-1207 showed a 6.9 point greater improvement compared to controls. This reached statistical significance and exceeded results from the initial 30-day study of NX-1207.
75% of the subjects in the trial were available for follow-up. Of these, 57% of the subjects treated with NX-1207 required no further treatment for BPH symptoms, and showed a mean improvement of 7.2 points in AUA scores.
BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.